Overview
WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.
Lobbying Costs
10,000€
Financial year: Jul 2022 - Jun 2023
Lobbyists (Full time equivalent)
0.1 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Aspen Pharmacare (ASP)
EU Transparency Register
204680631588-97 First registered on 22 May 2018
Goals / Remit
Aspen Pharmacare is a South-African pharmaceutical company.
Aspen operates with an established business presence in approximately 50 countries and supply products in more than 150 countries. We have a proud heritage dating back more than 160 years and are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.
We are a leading global player in specialty and branded pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to benefit the lives of patients using our products in more than 150 countries.
Aspen has identified Anaesthetics, High Potency & Cytotoxics, Antthrombotics and Nutritionals as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.
We operate 25 manufacturing facilities across 17 sites.Main EU files targeted
Aspen currently follows European policies, legislative files related to our Pharmaceuticals and any EU project(mainly in Anesthetesia and Oncology). We are particularly interested in European initiatives to support medicine affordability to patients and any initiatives to support production investment in the European countries.
Our domains of interest includes also Data Protection Regulation, Brexit consequences, Pharmaceutical Industry strategy, and EU pricing & trade Policy.Address
Head Office
Aspen Place 9 Rydall Vale Park Douglas Saunders Drive, La Lucia Ridge
Durban Gateway, 4321 - P O Box 25125
SOUTH AFRICAEU Office
Montgelasstrasse 14
München 81679
GERMANYWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 10% 1 Lobbyists (Full time equivalent)
0.1
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 09 Sep 2024
Name Start date End Date Mr Fabrice JOVER 29 May 2018 29 May 2019 Complementary Information
Current Position: Market Access & Tender Management Lead; overviewing EU Pharma Activities like Revision of EU general pharmaceutical legislation; EU Proposed directive on corporate sustainability due diligence, Relevance of the Green Deal,
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
https://www.aspenpharma.com/we-care/
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jul 2022 - Jun 2023
Lobbying costs for closed financial year
10,000€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
0€ - 10,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Application of King IV and compliance with the Companies
Act
The Group continuously strives to enhance its application of King IV and to ensure its ongoing compliance with the
South African Companies Act, 2008 (“Companies Act”). The application of the King IV principles and adoption of the various recommendations are published online.
https://www.aspenpharma.com/corporate-governance/Other activities
None declared
Meetings
Meetings
None declared